Medtronic is spinning off its Diabetes business into a new standalone company—creating waves across the healthcare tech landscape. The move, announced on May 21, 2025, aims to sharpen Medtronic’s focus on high-margin growth areas like robotics, neuromodulation, and cardiovascular innovation. The New Diabetes Company will emerge as the only scaled player with a fully integrated insulin management ecosystem, uniquely positioned for direct-to-consumer leadership. With over 8,000 employees and global reach, the spinout will also free up capital and increase Medtronic’s earnings potential. Why is Medtronic shedding a core business now? The answer may redefine the next chapter of digital chronic…
Author: Abhay Panchal
With 19 million more patients now eligible for colorectal cancer screening, the gastroenterology workforce is under mounting pressure—and private practices are at a breaking point. At DDW 2025, Dr. Asma Khapra warned that the percentage of fully independent GI practices has plunged from 30% to just 13% since 2019. As burnout, administrative burden, and staffing costs rise, private practices must rethink how they retain talent. Khapra offered a compelling strategy centered on the “Iceberg Model of Culture,” urging leaders to focus not just on visible perks, but on invisible elements like trust, fairness, and physician autonomy. Without action, the future…
Imec, in partnership with OnePlanet Research Center, introduced a highly miniaturized ingestible sensor for real-time gut health monitoring. Demonstrated live at ITF World 2025, the sensor is three times smaller than conventional capsule endoscopies and is the first to measure redox balance—an indicator of oxidative stress and inflammation—along with pH and temperature throughout the gastrointestinal tract. The device, just 2.1 cm long and 0.75 cm in diameter, offers a non-invasive alternative to traditional endoscopy and colonoscopy, which can be uncomfortable and limited in scope.
This wasn’t just a talk. It was a line in the sand. What if we’re solving the wrong problem in GI?What if the real question isn’t how efficiently we scope……but whether we should be doing them at all—at the scale we do today? At the AGA Tech Summit in Chicago, I posed a challenge: The future isn’t coming. It’s already here. And what happens in 2035 depends entirely on the actions we take—or avoid—today. GI is at a BIG inflection point. Most won’t realize until it’s already passed them by. There’s no rewinding this.This keynote is about more than technology. It’s about…
In a wide-ranging interview, Prof. Alexander Hann of the University Hospital Würzburg shared that while AI has improved adenoma detection rates in colonoscopies, the expected real-world impact—like reduced mortality—remains statistically insignificant. Despite over 40 randomized trials, the evidence has not led to widespread guideline endorsement. Concerns around over-reliance on AI, false positives, and “de-skilling” persist. Hann stresses that for AI to truly transform GI care, interdisciplinary research, robust multi-center datasets, and better endpoints are key.
Despite ranking as the fifth highest-paid specialty, many gastroenterologists report some of the lowest job satisfaction in medicine. According to a new report by Marit Health, stagnant wages—when adjusted for inflation—combined with CMS cuts and private equity consolidation are eroding compensation and autonomy in the field.
The upcoming IPOs of Hinge Health and Omada Health are more than capital events—they may mark a turning point for HealthTech M&A. According to Nelson Advisors, these high-profile debuts are poised to reset investor sentiment, validate virtual care models, and push up acquisition multiples for digital health companies. If the market rewards these IPOs, expect a ripple effect: rising benchmarks, faster deal activity, and renewed urgency among buyers who don’t want to miss the next breakout.
Obesity is rising in IBD populations, and GLP-1 receptor agonists may offer more than just weight control. In a series of new abstracts presented at Digestive Disease Week 2025, researchers from Mount Sinai explored GLP-1 use in IBD patients—and the results are promising. The medications were found to be safe, effective for weight loss, and even associated with improved disease remission, including in cases of perianal fistulizing Crohn’s disease.
Oath Surgical has emerged from stealth with a bold promise: to rebuild surgical care from the ground up. Backed by Oxford Science Enterprises and others, the startup launched OathOS—the first full-stack operating system that integrates AI software with its own surgeon-led, digitally powered surgical centers. With real-time data, automated recovery workflows, and performance-based payor alignment, Oath is redefining value-based outpatient care—not just improving the old model, but replacing it entirely.
SpotitEarly, a biotech startup from Israel, just launched in the U.S. with a bold idea—and $20.3 million in funding. Its approach? A home breath test analyzed by trained dogs and AI to detect early-stage cancers. Backed by published studies and a 94% accuracy rate, the test targets breast, lung, prostate, and colorectal cancers. With U.S. screening rates still alarmingly low, SpotitEarly believes it’s not just disrupting diagnostics—it’s rewriting the rules of early detection.